Vitiligo

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

Experts in dermatology review currently available JAK inhibitors for use in patients with dermatological conditions and highlight their differences.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, provide an overview of JAK inhibitors and their mechanisms of action in dermatology care.

Large numbers of vitiligo patients around the world have reported differing outcomes, with darker skin types expressing the more significant severity, according to new findings.

Research presented at EADV 2022 sees positive outcomes with the targeted therapy for patients of varied backgrounds with vitiligo.

Nonsegmental vitiligo not only affects the skin but can destroy melanocytes in other areas of the body including the eye, new research shows.

Patients over 21 years who developed acne presented with different clinical characteristics than younger patients.

Dr. Woolery-Lloyd shares her advice for vitiligo providers and tips for helpful communication with patients.

Drs. Pandya, Rosmarin and King share their enthusiasm about emerging therapies and data that is available for ruxolitinib.

A systematic literature review identifies 41 unique definitions for psoriasis remission among 106 studies.

A post-hoc analysis of clinical trial data found that psoriasis patients who were younger, less obese and had less severe psoriasis were more likely to achieve super-response to biologic treatment with guselkumab.

Biologic agents may reduce the risk of mental health disorders among patients with moderate-to-severe psoriasis who discontinued treatment with conventional systemic agents, researchers in Canada found.

Among flares identified in outpatient (53%), inpatient (36%), and emergency department (9%) settings, the most utilized treatments were topical corticosteroids (35%), opioids (21%), and other oral treatments.

The COVID-19 pandemic has drawn attention to acne associated with the prolonged use of medical face masks and raised awareness about the need for adequate screening, training and treatment of the condition.

Vitiligo clinical experts discuss the role of maintenance therapy in preventing recurrence of vitiligo.

Drs. Woolery-Lloyd, King and Pandya discuss time to re-pigmentation of different areas in vitiligo.

Investigators identified a correlation between severity of kidney-urinary tract complications and the affected protein involved with intermediate junctional epidermolysis bullosa (JEB).

Despite their tendency to present with more severe psoriasis compared with other races and ethnicities, Asian patients receive significantly less time with a dermatologist.

Drs. Woolery-Lloyd, Rosmarin and Pandya discuss various treatment options for vitiligo and when and where they might use them.

Dr. Rosmarin and other panelists share their thoughts on how to treat different areas of the body and the role of tattoos.

Although sharing a common feature of male predominance, alopecia did not seem to occur more frequently in AS patients.

45% of study participants were either dissatisfied or very dissatisfied with their current medical treatment.

Dr. Pandya shares his conversations with patients about re-pigmentation of segmental and non-segmental vitiligo and treatment options that exist.